K033915 is an FDA 510(k) clearance for the MODIFICATION TO SERAQUEST EB VCA IGG. Classified as Epstein-barr Virus, Other (product code LSE), Class I - General Controls.
Submitted by Quest Intl., Inc. (North Miami, US). The FDA issued a Cleared decision on January 16, 2004 after a review of 29 days - a notably fast clearance cycle.
This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3235 - the FDA microbiology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.
Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.